{"id":73,"date":"2019-02-27T18:01:51","date_gmt":"2019-02-27T18:01:51","guid":{"rendered":"https:\/\/www.libertymanagement.us\/fda-news\/?p=73"},"modified":"2019-04-16T19:39:09","modified_gmt":"2019-04-16T19:39:09","slug":"premarket-notification-510k","status":"publish","type":"post","link":"https:\/\/www.libertymanagement.us\/fda-news\/2019\/02\/27\/premarket-notification-510k\/","title":{"rendered":"PREMARKET NOTIFICATION 510(K)"},"content":{"rendered":"\n

A 510(k) or Premarket Notification<\/a> is the technical document required by the FDA to prove that the device to be marketed in the United States are as safe and effective, that is, substantially equivalent, to a legally marketed device which is not subject to PMA. A person who apply for 510K clearance must compare their device to similar legally marketed devices and create and support their substantial equivalence claims. The legally marketed devices to which uniformity is drawn is known as \u201cPredicate\u201d. <\/p>\n\n\n\n

The Submitter cannot market the device until he receives an order from FDA declaring a device substantially equivalent (SE). Once the device is declared as SE, it can be legally marketed in United States. SE determination will be made within 90 days of submission and also based on the information submitted by the submitter. Substantial equivalence is issued with respect to intended use, design, energy used or delivered, materials, chemical composition, manufacturing process, performance, safety, effectiveness, labeling, biocompatibility, standards, and other characteristics of the device. If FDA found out that the device is not substantially equivalent (SE), the submitter has to resubmit another 510K with new information or request a product classification via De Nova Classification process<\/a> or to submit a premarket approval application (PMA).<\/p>\n\n\n\n

Who needs to submit a 510K<\/strong><\/p>\n\n\n\n

The following are the four categories of 510K submitters to\nthe FDA.<\/p>\n\n\n\n

  1. Domestic manufacturers who introduce a new\ndevice to the U.S market. However only finished device manufacturers who\nmanufacture device according to their own specifications needs to submit 510K,\nwhereas the contract manufacturers are not required to submit a 510K.<\/li>
  2. Specification developers are required to submit\na 510K but not the contract manufacturers.<\/li>
  3. Re-packers or Re-labelers may be required to\nsubmit 510K if they change the labels or any other operations that affect the\ncondition of the device.<\/li>
  4. Foreign manufacturers\/exporters who introduce a\nnew device to the U.S market.<\/li><\/ol>\n\n\n\n

    All manufacturers, specification developers of Class II and Class III devices and certain Class I devices are required to follow 21 CFR 820 regulations<\/a>.<\/p>\n\n\n\n

    Liberty Management Group<\/a>, a leading FDA consulting group in the United States, provides assistance with preparation and submission of 510K to FDA, US agent service for foreign facilities, medical device establishment registration and listing with FDA.<\/p>\n\n\n\n

    Sudha S<\/p>\n\n\n\n

    Regulatory Consultant<\/p>\n\n\n\n

    Mial : office@libertymanagement.us<\/p>\n\n\n\n

    www.fdahelp.us<\/a><\/p>\n\n\n\n

    <\/p>\n","protected":false},"excerpt":{"rendered":"

    A 510(k) or Premarket Notification is the technical document required by the FDA to prove that the device to be marketed in the United States are as safe and effective, that is, substantially equivalent, to a legally marketed device which is not subject to PMA. A person who apply for 510K clearance must compare their … Continue reading “PREMARKET NOTIFICATION 510(K)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[2,13],"class_list":["post-73","post","type-post","status-publish","format-standard","hentry","category-fda-registration-medical-device","tag-fda-registration","tag-pre-market-notification-510k"],"_links":{"self":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/73","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/comments?post=73"}],"version-history":[{"count":1,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/73\/revisions"}],"predecessor-version":[{"id":74,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/73\/revisions\/74"}],"wp:attachment":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/media?parent=73"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/categories?post=73"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/tags?post=73"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}